Search results for " Follow-Up Studies"

showing 10 items of 116 documents

A follow-up study of a genome-wide association scan identifies a susceptibility locus for venous thrombosis on chromosome 6p24.1.

2010

International audience; To identify genetic susceptibility factors conferring increased risk of venous thrombosis (VT), we conducted a multistage study, following results of a previously published GWAS that failed to detect loci for developing VT. Using a collection of 5862 cases with VT and 7112 healthy controls, we identified the HIVEP1 locus on chromosome 6p24.1 as a susceptibility locus for VT. Indeed, the HIVEP1 rs169713C allele was associated with an increased risk for VT, with an odds ratio of 1.20 (95% confidence interval 1.13-1.27, p = 2.86 x 10(-9)). HIVEP1 codes for a protein that participates in the transcriptional regulation of inflammatory target genes by binding specific DNA …

MESH : Transcription Factors[SDV]Life Sciences [q-bio]Genome-wide association study030204 cardiovascular system & hematologyMESH : Chromosomes Human Pair 60302 clinical medicineGenetics(clinical)Genetics (clinical)GeneticsVenous Thrombosis0303 health sciencesMESH: Polymorphism Single NucleotideMESH : Polymorphism Single NucleotideMESH: Genetic Predisposition to DiseaseMESH: Follow-Up StudiesMESH: Transcription FactorsMESH : Venous ThrombosisMESH: Case-Control StudiesDNA-Binding ProteinsChromosomes Human Pair 6MESH : DNA-Binding ProteinsErratumMESH : Genome-Wide Association StudyMESH : Case-Control StudiesMESH: Chromosomes Human Pair 6Locus (genetics)BiologyPolymorphism Single NucleotideGenetic determinism03 medical and health sciencesReportGenetic predispositionGeneticsHumansGenetic Predisposition to DiseaseAlleleGene030304 developmental biologyMESH: Humans[ SDV ] Life Sciences [q-bio]MESH : Humanslinking inflammation protein atherothrombosis sequence riskCase-control studyChromosomeMESH : Follow-Up StudiesCase-Control StudiesMESH: Genome-Wide Association StudyMESH: Venous ThrombosisMESH : Genetic Predisposition to Disease030217 neurology & neurosurgeryMESH: DNA-Binding ProteinsFollow-Up StudiesGenome-Wide Association StudyTranscription Factors
researchProduct

Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.

2016

IF 10.383; International audience; OBJECTIVES: Cancer may be a complication of inflammatory bowel disease (IBD) or its treatment. In elderly onset IBD patients the risk of malignancy is of particular concern. We studied this risk in a population-based cohort of elderly onset IBD patients.METHODS: In a French population-based cohort, we identified 844 patients aged >60 years at IBD diagnosis from 1988 to 2006, including 370 Crohn's disease (CD) and 474 ulcerative colitis (UC). We compared incidence of cancer among IBD patients with that observed in the French Network of population-based Cancer Registries (FRANCIM). Confidence interval (CI) was estimated assuming a Poisson-specific law for ra…

MESH: CarcinomaMaleNonmelanoma Skin-CancerInflammatory bowel disease0302 clinical medicineAdrenal Cortex HormonesAzathioprineMESH: IncidenceAge of OnsetAged 80 and overeducation.field_of_studyMESH: Middle AgedRheumatoid-ArthritisIncidenceGastroenterologyMESH: Follow-Up StudiesMESH: Anti-Inflammatory Agents Non-Steroidal3. Good health030220 oncology & carcinogenesisCohort030211 gastroenterology & hepatology[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: Immunosuppressive Agentsmedicine.medical_specialtyMESH: Age of OnsetMESH: Colitis Ulcerativedigestive systemMESH: Adrenal Cortex Hormones03 medical and health sciencesIntestinal NeoplasmsHumansCrohns-DiseaseeducationMESH: Intestinal NeoplasmsMESH: Protective FactorsMESH: AzathioprineAgedRetrospective StudiesMESH: HumansMESH: Crohn DiseaseTumor Necrosis Factor-alphaMESH: Retrospective Studiesmedicine.diseaseMESH: Inflammatory Bowel DiseasesInflammatory Bowel Diseasesdigestive system diseasesLymphoproliferative DisordersMethotrexateMESH: Tumor Necrosis Factor-alphaColitis UlcerativeComplicationMESH: FemaleProspective Observational CohortTime FactorsMESH: RegistriesMESH: Proportional Hazards ModelsMaintenance TherapyMESH: Aged 80 and overMESH: Lymphoproliferative DisordersCrohn DiseaseMESH: Risk FactorsRisk FactorsNeoplasmsMESH: NeoplasmsRegistriesUlcerative-ColitisMesalamineMESH: AgedIncidence (epidemiology)Anti-Inflammatory Agents Non-SteroidalMetaanalysisMiddle AgedhumanitiesMESH: MethotrexateFemaleFranceFrench PopulationColorectal NeoplasmsImmunosuppressive AgentsMESH: Myeloproliferative DisordersPopulationColorectal-CancerIncreased RiskInternal medicinemedicineProportional Hazards ModelsMyeloproliferative DisordersHepatologybusiness.industryMESH: Time FactorsCarcinomaCancerRetrospective cohort study[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: MesalamineProtective FactorsMESH: MaleMESH: FranceAge of onsetbusinessMESH: Colorectal NeoplasmsFollow-Up StudiesThe American journal of gastroenterology
researchProduct

Fried potato consumption is associated with elevated mortality: an 8-y longitudinal cohort study

2017

Background: Few studies have assessed the association between potato consumption and mortality. Objective: We investigated whether potato consumption (including fried and unfried potatoes) is associated with increased premature mortality risk in a North American cohort. Design: A longitudinal analysis included 4440 participants aged 45-79 y at baseline with an 8-y follow-up from the Osteoarthritis Initiative cohort study. Potato consumption (including fried and unfried potatoes) was analyzed by using a Block Brief 2000 food-frequency questionnaire and categorized as ≤1 time/mo, 2-3 times/mo, 1 time/wk, 2 times/wk, or ≥3 times/wk. Mortality was ascertained through validated cases of death. T…

Male0301 basic medicineGerontologyMedicine (miscellaneous)0302 clinical medicineRisk FactorsCause of DeathMedicineCookingLongitudinal StudiesProspective Studies030212 general & internal medicineMortality; Osteoarthritis Initiative; Potato; Risk factor; Aged; Cooking; Diet Surveys; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Middle Aged; Plant Tubers; Proportional Hazards Models; Prospective Studies; Risk Factors; Cause of Death; Diet; Feeding Behavior; Solanum tuberosum; Medicine (miscellaneous); Nutrition and DieteticsLongitudinal cohortProspective cohort studyCause of deathMortality; Osteoarthritis Initiative; Potato; Risk factor; Medicine (miscellaneous); Nutrition and DieteticsNutrition and Dieteticsmortality potato risk factor Osteoarthritis Initiative.Confoundingfood and beveragesMiddle AgedPlant Tubersrisk factorOsteoarthritis InitiativepotatoFemalePotatoCohort studyDiet SurveysOsteoarthritis Initiative.03 medical and health sciencesAnimal scienceJournal ArticleHumansMortalityRisk factorAgedProportional Hazards ModelsSolanum tuberosumConsumption (economics)030109 nutrition & dieteticsProportional hazards modelbusiness.industryfungiFeeding BehaviormortalityDietRisk factorbusinessFollow-Up StudiesThe American Journal of Clinical Nutrition
researchProduct

Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry

2021

Abstract Objectives To investigate survival of IL-1 inhibitors in monogenic autoinflammatory disorders (mAID) through drug retention rate (DRR) and identify potential predictive factors of drug survival from a real-life perspective. Patients and methods Multicentre retrospective study analysing patients affected by the most common mAID treated with anakinra or canakinumab. Survival curves were analysed with the Kaplan-Meier method. Statistical analysis included a Cox-proportional hazard model to detect factors responsible for drug discontinuation. Results Seventy-eight patients for a total of 102 treatment regimens were enrolled. The mean treatment duration was 29.59 months. The estimated D…

Male0301 basic medicineTime FactorsSettore MED/16 - REUMATOLOGIAInterleukin-1beta0302 clinical medicineSettore MED/38 - Pediatria Generale E SpecialisticaMonoclonalPharmacology (medical)RegistriesHumanizedmedia_commonIL-1 anakinra canakinumab innovative biotechnologies monogenic autoinflammatory disorders personalized medicinepersonalized medicineMiddle AgedPenetranceTreatment OutcomeAnakinraAntirheumatic AgentsAutoinflammationIL-1; anakinra; canakinumab; innovative biotechnologies; monogenic autoinflammatory disorders; personalized medicine; Adult; Antibodies Monoclonal Humanized; Antirheumatic Agents; Female; Follow-Up Studies; Hereditary Autoinflammatory Diseases; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Male; Middle Aged; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult; RegistriesFemalemedicine.drugAdultDrugmedicine.medical_specialtymedia_common.quotation_subjectAntibodies Monoclonal HumanizedcanakinumabAntibodiesYoung Adult03 medical and health sciencesinnovative biotechnologiesRheumatologyInternal medicinemedicineHumansAdverse effectSurvival analysismonogenic autoinflammatory disordersRetrospective Studies030203 arthritis & rheumatologyAnakinraIL-1business.industryHereditary Autoinflammatory DiseasesRetrospective cohort studyInterleukin 1 Receptor Antagonist ProteinCanakinumab030104 developmental biologyObservational studybusinessFollow-Up Studies
researchProduct

“Better explanations” in multiple sclerosis diagnostic workup

2019

BackgroundThe exclusion of other diseases that can mimic multiple sclerosis (MS) is the cornerstone of current diagnostic criteria. However, data on the frequency of MS mimics in real life are incomplete.MethodsA total of 695 patients presenting with symptoms suggestive of MS in any of the 22 RIREMS centers underwent a detailed diagnostic workup, including a brain and spinal cord MRI scan, CSF and blood examinations, and a 3-year clinical and radiologic follow-up.FindingsA total of 667 patients completed the study. Alternative diagnoses were formulated in 163 (24.4%) cases, the most frequent being nonspecific neurologic symptoms in association with atypical MRI lesions of suspected vascular…

Male404241Longitudinal StudieDisease0302 clinical medicineMultiple SclerosiDiagnosisMedicine030212 general & internal medicineProspective StudiesLongitudinal StudiesProspective cohort studymedicine.diagnostic_testMagnetic Resonance Imagingclinical practiceatypical MRI lesionsMS mimicsDisease ProgressionFemaleSettore MED/26 - NeurologiaRadiologyHumanAdultmultiple sclerosis; diagnostic criteria; atypical MRI lesions; MS mimics; clinical practicemedicine.medical_specialtyMultiple Sclerosis2omarkers / metabolism Diagnosis Differential Female Follow-Up Studies Humans Longitudinal Studies Magnetic Resonance Imaging Male Multiple Sclerosis / diagnosis* Prospective StudiesArticleFollow-Up StudieDiagnosis Differential03 medical and health sciencesHumansNeuromyelitis opticabusiness.industryMultiple sclerosisAdult; Biomarkers; Diagnosis Differential; Female; Follow-Up Studies; Humans; Longitudinal Studies; Magnetic Resonance Imaging; Male; Multiple Sclerosis; Prospective StudiesMagnetic resonance imagingOdds ratioBiomarkermedicine.disease101MigraineDifferentialdiagnostic criteriaNeurology (clinical)Differential diagnosisbusiness030217 neurology & neurosurgeryBiomarkersFollow-Up StudiesNeurology
researchProduct

Cancer in Crohn's Disease patients treated with infliximab: a long-term multicenter matched pair study

2011

Background: The long-term risk of neoplasia in Crohn's disease (CD) patients treated with infliximab is undefined. The aim was to assess, in a multicenter, matched-pair study, whether infliximab use in CD is associated with an increased frequency of neoplasia in the long term. Methods: A multicenter, long-term, matched-pair study was conducted in 12 referral inflammatory bowel disease (IBD) centers. An initial cohort of 808 CD patients, including 404 infliximab-treated (CD-IFX) and 404 matched CD controls never treated with infliximab (CD-C) studied from 1999 to 2004, was followed up for an additional 4 years (2004–2008). Cases and controls were matched for: sex, age (±5 years), CD site, fo…

MaleAdultmedicine.medical_specialtyTime FactorsCROHN'S DISEASECrohn’s disease infliximab cancer matched-pairInflammatory bowel diseaseGastroenterologyAntibodiesCohort StudiesGastrointestinal AgentsCrohn DiseaseInternal medicineNeoplasmsINFLIXIMABMonoclonalmedicineImmunology and AllergyHumanstherapeutic use Case-Control Studies Cohort Studies Crohn Diseaseetiology Survival Rate Time Factors Treatment OutcomeSurvival rateAgedCancer Infliximab Inflammatory bowel diseaseCrohn's diseasebusiness.industryGastroenterologyCase-control studyAntibodies MonoclonalCancerMiddle Ageddrug therapy Female Follow-Up Studies Gastrointestinal Agenttherapeutic use Humans Male Middle Aged Neoplasmmedicine.diseaseTreatment Outcome; Male; Time Factors; Survival Rate; Middle Aged; Female; Neoplasms; Gastrointestinal Agents; Humans; Cohort Studies; Follow-Up Studies; Aged; Adult; Antibodies Monoclonal; Case-Control Studies; Crohn DiseaseCANCERInfliximabSurgerySurvival RateSettore MED/18 - Chirurgia GeneraleTreatment OutcomeCase-Control StudiesCohortFemaleAdult Aged Antibodiebusinessmedicine.drugCohort studyFollow-Up Studies
researchProduct

Bronchial hyperresponsiveness in children with atopic rhinitis: a 7-year follow-up

2004

Background:  A high prevalence of bronchial hyperresponsiveness (BHR) was found in atopic subjects with rhinitis. Those subjects may be at higher risk for developing bronchial asthma. We evaluated, in a 7-year follow-up, BHR and atopy in a homogeneous population of nonasthmatic children with allergic rhinitis (AR), and their role in asthma development. Methods:  Twenty-eight children (6–15 years) with AR were studied. At enrollment (T0), skin tests, total serum IgE assay, peak expiratory flow (PEF) monitoring and methacholine (Mch) bronchial challenge were performed. BHR was computed as the Mch dose causing a 20% forced expiratory volume (FEV)1 fall (PD20FEV1) and as dose–response slope (DR…

MaleAllergymedicine.medical_specialtyAdolescentAtopic RhinitisImmunologyPopulationLongitudinal StudieFollow-Up StudieAtopychildrennonspecific bronchial hyperresponsivenessInternal medicinemedicineHypersensitivityHumansImmunology and AllergyLongitudinal StudiesHumans; Disease Progression; Asthma; Child; Rhinitis; Longitudinal Studies; Hypersensitivity; Pulmonary Ventilation; Bronchial Hyperreactivity; Follow-Up Studies; Adolescent; Female; MaleeducationChildRhinitiRhinitisAsthmaeducation.field_of_studyallergic rhinitis; asthma; children; methacholine test; nonspecific bronchial hyperresponsivenessallergic rhinitisbusiness.industryRespiratory diseasemethacholine testrespiratory systemasthmamedicine.diseaserespiratory tract diseasesBronchial hyperresponsivenessImmunologyDisease ProgressionMethacholineFemaleBronchial HyperreactivitybusinessPulmonary VentilationFollow-Up Studiesmedicine.drugHuman
researchProduct

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study.

2018

© 2018 The Authors.

MaleCancer ResearchBoronic Acid[SDV]Life Sciences [q-bio]bortezomib ; global ; observational study ; routine practice ; stem cell transplantationSalvage therapyPractice PatternsDexamethasoneBortezomibRoutine practice0302 clinical medicineBortezomib; Global; Observational study; Routine practice; Stem cell transplantationhemic and lymphatic diseasesObservational studyAntineoplastic Combined Chemotherapy Protocols80 and overProspective StudiesPractice Patterns Physicians'Prospective cohort studyLenalidomideComputingMilieux_MISCELLANEOUSMultiple myelomaAged 80 and overBortezomibStem cell transplantationGlobalHematologyMiddle AgedBoronic Acids3. Good healthThalidomideSurvival RateTreatment OutcomeLocalOncology030220 oncology & carcinogenesisBortezomib; Global; Observational study; Routine practice; Stem cell transplantation; Hematology; Oncology; Cancer ResearchFemaleMultiple MyelomaBortezomib; Global; Observational study; Routine practice; Stem cell transplantation; Adult; Aged; Aged 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence Local; Prospective Studies; Survival Rate; Thalidomide; Treatment Outcome; Practice Patterns Physicians'; Salvage Therapymedicine.drugHumanAdultmedicine.medical_specialty/NOFollow-Up Studie03 medical and health sciencesInternal medicinemedicineHumansSurvival rateLenalidomideAgedSalvage TherapyPhysicians'Antineoplastic Combined Chemotherapy Protocolbusiness.industrySettore MED/15medicine.diseaseTransplantationThalidomideSettore MED/15 - MALATTIE DEL SANGUEProspective StudieNeoplasm RecurrenceNeoplasm Recurrence Localbusiness030215 immunologyFollow-Up StudiesClinical lymphoma, myelomaleukemia
researchProduct

R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted …

2013

Purpose Although rituximab (R) is commonly used for patients with advanced follicular lymphoma (FL) requiring treatment, the optimal associated chemotherapy regimen has yet to be clarified. Patients and Methods We conducted an open-label, multicenter, randomized trial among adult patients with previously untreated stages II to IV FL to compare efficacy of eight doses of R associated with eight cycles of cyclophosphamide, vincristine, and prednisone (CVP) or six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or six cycles of fludarabine and mitoxantrone (FM). The principal end point of the study was time to treatment failure (TTF). Results There were 534 patients…

MaleCancer ResearchLymphomamedicine.medical_treatmentFollicular lymphomaCHOPGastroenterologyAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesLymphoma FollicularNON-HODGKINS-LYMPHOMASAdult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Neoplasm Staging; Prednisone; Prognosis; Prospective Studies; Survival Rate; Vidarabine; Vincristine; Oncology; Cancer ResearchCHEMOTHERAPYMiddle AgedPrognosisChemotherapy regimenFludarabineSurvival RateOncologyVincristineFemaleFLUDARABINECLINICAL-TRIALSVidarabinemedicine.drugAdultVincristinemedicine.medical_specialtyAdult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Neoplasm Staging; Prednisone; Prognosis; Prospective Studies; Survival Rate; Vidarabine; VincristineInternal medicinemedicineHumansRITUXIMABSurvival rateCyclophosphamideRESPONSE CRITERIAAgedNeoplasm StagingChemotherapyMitoxantronebusiness.industryFollicularmedicine.diseasePHASE-IIISurgery1ST-LINE TREATMENTDoxorubicinPrednisoneMitoxantroneNeoplasm GradingbusinessFollow-Up StudiesJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

Influence of sample return time and ambient temperature on the performance of an immunochemical faecal occult blood test with a new buffer for colore…

2016

IF 2.415; International audience; The haemoglobin concentration measured by faecal immunochemical tests (FIT) may be decreased in cases of delayed sample return or high temperature. It is an issue of great importance. The aim of this study was to investigate the effects of sample return time and of season on the performance of an FIT (FOB-Gold) with a new buffer. The study included 20 371 participants involved in the French organized colorectal cancer (CRC) screening programme. The probability of a positive screening test, detection rates and positive predictive values for CRC and advanced adenoma were analysed according to sample return time and season of screening. A sample of positive FI…

MaleCancer ResearchMultivariate analysisTime FactorsEpidemiologyColorectal cancerMESH: Reagent Kits DiagnosticMESH : AgedMESH : HemoglobinsMESH : Early Detection of Cancer[ SDV.CAN ] Life Sciences [q-bio]/CancerReturn timeScreening programmeImmunoenzyme TechniquesHemoglobinsMESH : Specimen HandlingMESH : FemaleMESH : Neoplasm StagingMESH : Reagent Kits DiagnosticMESH : TemperatureEarly Detection of CancerMESH: AgedMESH: Middle AgedMESH : PrognosisTemperatureMESH: Follow-Up StudiesMESH: Neoplasm StagingMiddle AgedPrognosisPredictive valueMESH: TemperatureMESH: HemoglobinsMESH : Occult BloodOncologyColorectal cancer screeningOccult BloodFemaleSeasonsMESH : Colorectal NeoplasmsColorectal NeoplasmsMESH : Time FactorsAdenomamedicine.medical_specialtySample (material)MESH : Male[SDV.CAN]Life Sciences [q-bio]/CancerMESH: PrognosisSpecimen HandlingAnimal scienceMESH : Immunoenzyme TechniquesmedicineHumansMESH: Early Detection of CancerMESH : Middle AgedMESH: Specimen HandlingMESH: Immunoenzyme TechniquesAgedNeoplasm StagingMESH: AdenomaMESH: HumansMESH : Seasonsbusiness.industryMESH: Time FactorsMESH : HumansPublic Health Environmental and Occupational HealthMESH : Follow-Up Studiesmedicine.diseaseMESH: MaleSurgeryMESH : AdenomaReagent Kits DiagnosticFaecal occult blood testbusinessMESH: Occult BloodMESH: FemaleMESH: SeasonsMESH: Colorectal NeoplasmsFollow-Up Studies
researchProduct